212Pb MSLN-Radio-DARPin / Molecular Partners, Orano - LARVOL DELTA

Preclinical characterization of a Lead-212 Radio-DARPin Therapeutic to selectively target membrane-bound mesothelin in solid tumors (SNMMI 2025) - "The biodistribution of these anti-MSLN 212Pb Radio-DARPins was assessed in MSLN-expressing xenograft tumor models... By using our DARPin platform we achieved highly specific DARPin-based targeting of MSLN expressed on cancer cells that was not impaired by the presence of sMSLN. Labelled with 212Pb, our anti-MSLN Radio-DARPins showed a favorable preclinical biodistribution profile which justifies further development of this RDT approach for the treatment of patients with MSLN-positive solid tumors."

Preclinical • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • MSLN

Development of 212Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors (AACR 2025) - "We designed an approach to specifically target MSLN expressed on cancer cells employing DARPin technology combined with 212Pb. Our early preclinical results indicative of a favorable biodistribution profile of the 212Pb labelled MSLN DARPin motivate further development of this RDT for the treatment of patients with MSLN-positive solid tumors."

Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • MSLN

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 (GlobeNewswire) - "The MSLN x 212Pb Radio-DARPin poster outlines how MSLN may be a promising target for ovarian cancer due to its differentiated expression profiles - high in tumor, and lower in healthy tissues. High levels of shed MSLN, however, can act as a decoy receptor and have historically hampered the development of MSLN-targeted therapeutics. Molecular Partners has leveraged the unique properties of DARPins to develop a Radio-DARPin able to selectively bind membrane-bound MSLN without being impacted by shed MSLN. In vivo results show a favorable biodistribution with strong tumor accumulation of the Radio-DARPin in a MSLN-overexpressing model in mice."

Preclinical • Oncology